In this study, participants will receive either intranasal anti-IgE-antibodies (n=5) or intranasal allergen (n=5) or intranasal placebo (n=5). Blood samples will be obtained before nasal administration of study drugs and 3, 5 and 8 weeks thereafter. In the serum samples, specific and total IgE levels will be assessed.

开始日期2012-11-01

申办/合作机构

Medical University of Vienna

100 项与 AVP-13358 相关的临床结果

登录后查看更多信息

100 项与 AVP-13358 相关的转化医学

登录后查看更多信息

100 项与 AVP-13358 相关的专利（医药）

登录后查看更多信息

372

项与 AVP-13358 相关的文献（医药）

2024-08-14·Retina

Novel Agents in the Management of Diabetes and Risk of Worsening Diabetic Retinopathy

Review

作者: McGill, Janet B. ; Rajagopal, Rithwick

Purpose:Novel therapies for diabetes have potent effects on glycemic control, obesity and cardiovascular risk reduction but some, including the popular drug semaglutide, have also been implicated in worsening of diabetic retinopathy (DR). Given the ubiquity of these new agents, understanding the risks to vision is important. Here we review the data for several newly available agents in terms of systemic efficacy and retinal safety.Methods:Literature review.Results:Novel antihyperglycemic treatments include incretin mimetics and enhancers, sodium-glucose cotransporter inhibitors, long-acting insulins, and insulin delivery systems. All improve glycemic control and some have been shown to reduce major cardiovascular outcomes. In a pivotal trial, semaglutide was associated with ∼75% increased risk of DR worsening. The novel long-acting insulin icodec, formulated for once-weekly dosing, showed increased risk of DR worsening over a once-daily insulin. No other recent antihyperglycemic agent was associated with DR worsening, though following the semaglutide trials, nearly all studies excluded patients with pre-existing DR. Cases of DR worsening were rare in all instances. Dedicated safety studies for semaglutide in DR are currently underway.Conclusion:For most patients being considered for treatment with a novel anti-hyperglycemic agent, benefits on systemic metabolic and cardiovascular health are very likely to outweigh potential retinal harms. Although the true risks of the new agents on DR are unclear since their safety data come from secondary endpoints, the most vulnerable patients are those with pre-existing high-risk DR, poor baseline glycemic control and using insulin.

2024-08-01·Biochemical Pharmacology

Metformin suppresses gastric cancer progression by disrupting the STAT1-PRMT1 axis

Article

作者: Chen, Yanyan ; Wang, Kaiqing ; Yao, Surui ; Huang, Zhaohui ; Fei, Bojian ; Zhang, Meimei ; Wang, Suzeng ; Gong, Zhicheng

Gastric cancer (GC) is a common form of cancer and the leading cause of cancer-related deaths worldwide. Chemotherapy is the primary treatment for patients with unresectable or partially resectable GC. However, its adverse effects and chemoresistance greatly restrict its applicability and efficacy. Although HER2-targeted therapy and immunotherapy have been successfully used for GC treatment, their beneficial population is limited. To expand the range of cancer treatments, drug repurposing has emerged as a promising strategy. In this study, we evaluated the potential of Metformin, an oral anti-hyperglycemic agent, to suppress GC progression both in vivo and in vitro. Functional investigations showed that Metformin significantly inhibits GC proliferation and migration. Furthermore, we discovered that Metformin bound and disrupted STAT1 phosphorylation, inhibiting PRMT1 expression and consequently GC progression. In conclusion, our study not only provides further evidence for the anti-GC role of Metformin but also identifies the direct target mediating the tumor-inhibitory effects of Metformin in GC.

2024-08-01·Heliyon

Efficacy of anti-hyperkalemic agents during cardiopulmonary resuscitation in out-of-hospital cardiac arrest

Article

作者: Park, Jong Eun ; Yoon, Hee ; Lee, Se Uk ; Jeong, Daun ; Hwang, Sung Yeon ; Kim, Taerim ; Cha, Won Chul ; Shin, Tae Gun ; Sim, Min Seob ; Jo, Ik Joon ; Lee, Gun Tak

AimWe assessed the efficacy of anti-hyperkalemic agents for alleviating hyperkalemia and improving clinical outcomes in patients with out-of-hospital cardiac arrest (OHCA).MethodsThis was a single-center, retrospective observational study of OHCA patients treated at tertiary hospitals between 2010 and 2020. Adult patients aged 18 or older who were in cardiac arrest at the time of arrival and had records of potassium levels measured during cardiac arrest were included. A linear regression model was used to evaluate the relationship between changes in potassium levels and use of anti-hyperkalemic medications. Cox proportional hazards regression analysis was performed to analyze the relationship between the use of anti-hyperkalemic agents and the achievement of return of spontaneous circulation (ROSC).ResultsAmong 839 episodes, 465 patients received anti-hyperkalemic medication before ROSC. The rate of ROSC was higher in the no anti-hyperkalemic group than in the anti-hyperkalemic group (55.9 % vs 47.7 %, P = 0.019). The decrease in potassium level in the anti-hyperkalemic group from pre-ROSC to post-ROSC was significantly greater than that in the no anti-hyperkalemic group (coefficient 0.38, 95 % confidence interval [CI], 0.13-0.64, P = 0.003). In Cox proportional hazards regression analysis, the use of anti-hyperkalemic medication was related to a decreased ROSC rate in the overall group (adjusted hazard ratio [aHR] 0.66, 95 % CI, 0.54-0.81, P < 0.001), but there were no differences among subgroups classified according to initial potassium levels.ConclusionsAnti-hyperkalemic agents were associated with substantial decreases in potassium levels in OHCA patients. However, administration of anti-hyperkalemic agents did not affect the achievement of ROSC.

项与 AVP-13358 相关的新闻（医药）

2022-08-08

·PRNewswire

United BioPharma's Study Reveals New Class of Monoclonal Antibody for Effective Relief of Urticaria Symptoms

TAIPEI, Aug. 5, 2022 /PRNewswire/ -- United BioPharma (UBP) today announced their latest results featuring unprecedented and unique functional characteristics of UB-221 monoclonal antibody in the phase I single-dose clinical trial, with chronic spontaneous urticaria (CSU) patients, to exhibit durable disease symptom relief. The results were published in the latest Journal of Clinical Investigation (JCI). A New Treatment Option for CSU The chronic spontaneous urticaria (CSU) has known to be caused by a type of protein or antibodies produced by the immune system, known as Immunoglobulin E (IgE). While the existing approved CSU therapy (omalizumab; Xolair® ) and investigational drug (ligelizumab), have exerted positive reaction to reduce the disease symptoms over the last two decades, United BioPharma's latest results have shown that the potential of a newer class of anti-IgE monoclonal antibody UB-221 has superior efficacy in CSU and can prolong the suppression of the disease symptoms. In the study, UB-221 has proven to be a potent IgE neutralizer and a significant inhibitor of IgE neo-synthesis. Meaning, UB-221 binds IgE with a higher affinity and inhibits IgE production at a far greater scale in comparison with other anti-IgE antibodies like omalizumab and ligelizumab. The study also suggests this new class of monoclonal antibody shows promise for the prevention of the development of allergic symptoms, through targeting both high-affinity IgE receptor (FcϵRI) and low affinity IgE receptor (CD23) pathways. In addition, a notable observation of the study is that UB-221 in free form can interact unrestricted with CD23. This unprecedented feature not found in any other anti-IgE antibodies, supports the contention that it could be of benefit to target IgE toward the non-inflammatory CD23 pathway. In other words, UB-221 can down-regulate IgE production and reduce serum IgE levels in urticaria patients. Other findings highlighted from the data published in the JCI include: In studies with animal models, such as cynomolgus macaques and human IgE (ε, κ)-transgenic hIGHE (immunoglobulin heavy epsilon)-knockin mice, a single dose of UB-221 can induce a rapid, profound reduction of serum IgE. The prolong suppression of urticaria symptoms and reduction of serum IgE levels suggests that a single dose of >2.0 mg/kg could potentially allow UB-221 to be administered every 3 to 6 months and achieve complete response (UAS7 = 0) or well controlled stage (UAS7 ≤ 6) in the treatment of CSU. Advances in UB-221 for Allergic Diseases Recent studies have shown that the combined prevalence of allergic diseases has increased to affect more than 30% of the world population. The condition underscores unmet medical need, burden on healthcare systems and the global economy as well. In response to the situation, UB-221 is being developed as therapeutic biologics. It aims to treat various types of allergic (atopic) diseases, including chronic spontaneous urticaria, food allergy, atopic dermatitis, asthma, and allergic rhinitis. About United BioPharma United BioPharma (UBP) is a late clinical stage biopharmaceutical company that is dedicated to the research, development and manufacture of novel monoclonal antibodies (mAbs) for infectious and immunological diseases. UBP is headquartered in Taiwan, with subsidiary companies in Shanghai and Yangzhou China, and liaison offices in the U.S. The company has built a passionate global team, developing high-quality therapeutic mAbs and delivering affordable treatments to bring the patients better quality of life. For more information, please visit the website at: http://www.unitedbiopharma.com

抗体合作

2022-07-01

·BioSpace

IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- IgGenix Inc., a biotechnology company taking a revolutionary approach to directly alleviate allergic disease, today announced insights from its novel SeqSifter™ single-cell RNA-sequencing discovery platform demonstrating the potential for IgE antibody re-engineering in tree nut allergy. These data will be presented during the 2022 European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress, taking place in Prague, Czech Republic on July 1-3, 2022. Highlights from the EAACI Data Through an unbiased discovery approach IgGenix has discovered and re-engineered IgE antibodies as IgG antibodies to block the reactive molecules underlying allergic disease. Monoclonal antibodies (mAbs) discovered from tree nut allergic individuals exhibited a range of affinities, with many demonstrating high affinity in the sub-nanomolar range. Select mAbs studied exhibited cross-reactivity to multiple tree nut allergens, including the pairs of cashew and pistachio, as well as pecan and walnut – highlighting potential future use of this therapeutic model to address tree nut co-allergies. A more targeted therapeutic approach for patients has the potential to address key allergens directly with better safety than allergen-oriented approaches and a quicker onset of action. “These insights provide a molecular basis for clinical co-allergy to multiple tree nuts and provide an encouraging beginning for developing therapeutics to target the key allergens driving tree nut allergy,” said Derek Croote, Co-Founder and Chief Technical Officer of IgGenix. “At IgGenix, we are developing a novel approach to treating allergic disease. These data are the potential basis for treatments that may block and prevent life-threatening allergic reactions.” Title: Cross-reactive, High-affinity Monoclonal IgE Antibodies Underlie Tree Nut Co-Allergy (#100220) Authors: Croote D., Creeks P., Romero J., Sohail S., Lowman H.B., Wong J. J.W. Presenter: Derek Croote, Ph.D. The abstract can be accessed here. About IgGenix IgGenix is a privately held biotechnology company taking a revolutionary approach to directly alleviate food and other severe allergies by reengineering key antibodies involved in the allergic cascade. Founded based on research by Stephen Quake, Kari Nadeau, and Derek Croote of a novel discovery platform developed at Stanford University, IgGenix isolates rare allergen-specific IgE antibodies responsible for allergic reactions and transforms them into IgG antibodies. These therapeutic IgG antibodies are designed to alleviate and possibly prevent life-threatening allergic reactions, saving lives and reducing the constant fear that affects people living with severe allergies.

抗体

100 项与 AVP-13358 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
过敏性哮喘	临床1期	美国	Avanir Pharmaceuticals, Inc.	-
哮喘	临床1期	-	Avanir Pharmaceuticals, Inc.	-
过敏性鼻炎	临床1期	美国	Avanir Pharmaceuticals, Inc.	-